Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00168519
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : December 15, 2009
Sponsor:
Collaborators:
National Health and Medical Research Council, Australia
Hoffmann-La Roche
Diabetes Australia
Information provided by:
Baker Heart Research Institute

Tracking Information
First Submitted Date  ICMJE September 14, 2005
First Posted Date  ICMJE September 15, 2005
Last Update Posted Date December 15, 2009
Study Start Date  ICMJE October 2002
Primary Completion Date Not Provided
Current Primary Outcome Measures  ICMJE
 (submitted: December 14, 2009)
glucose metabolism [ Time Frame: 3 hours ]
Original Primary Outcome Measures  ICMJE Not Provided
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes
Official Title  ICMJE Contraction Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes
Brief Summary The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise.
Detailed Description

Aim 1: To determine whether acute infusion of sodium nitroprusside, an NO donor, increases leg glucose uptake at rest in patients with type 2 diabetes.

Twenty male type 2 diabetic patients aged between 30 and 60 years will be recruited from our clinic and through advertisement. The inclusion criteria:

  • non-smokers
  • free of overt coronary disease (stress ECG)
  • body mass index < 35 kg.m-2
  • fasting plasma glucose > 7 mmol.L-1 and / or post 75 gm oral glucose load plasma glucose levels of > 11.1 mmol.L-1
  • unmedicated (diet controlled)

The leg blood flow (thermodilution) and glucose uptake responses (arterial-venous differences) to three cumulative doses of sodium nitroprusside (0.1, 0.3 and 0.6 ug.kg-1.min-1, 10 mins per dose) infused into the femoral artery using techniques established in our laboratory will be assessed. Doses are based on our extensive unpublished observations and have been calculated to lie on the linear part of the dose-response curve and to induce local and not systemic hemodynamic effects. As a control we will also assess responses to the nitrate independent vasodilator, Verapamil (Isoptin) (1, 3 and 6 ug.kg-1.min-1 Doses). Verapamil is a calcium channel antagonist which causes vasodilatation by direct actions on the smooth muscle. Doses will be titrated to give similar blood flow responses and the two drugs will be administered in randomized order with a 60 min wash-out period. Verapamil doses will be determined in pilot experiments. Vastus lateralis biopsies will be performed at baseline and after the highest dose of each drug and cGMP and GLUT-4 translocation measured.

A single Vastus lateralis biopsy will be performed as a comparison against type 2 diabetics.

Significance: This study will determine whether acute NO supplementation stimulates muscle GLUT-4 translocation and glucose uptake in patients with type 2 diabetes.

Pilot Study: To determine whether oral nitrates increase exhaled NO levels in healthy volunteers & to compare isosorbide mononitrate (ISMN) with pentaerythritol tetranitrate (PETN) to determine which drug is more effective in increasing exhaled NO.

Fifteen healthy male volunteers (as determined via a medical screening) aged between 18 and 65 years will be recruited through advertisement. The inclusion criteria for healthy controls will be:

  • non-smokers
  • free of overt coronary disease (ECG)
  • body mass index < 30 kg.m-2
  • fasting plasma glucose < 6.1 mmol.L-1
  • unmedicated

Blood samples will be obtained and an oral glucose tolerance test (OGTT) performed. Baseline exhaled nitric oxide (NO) and pulmonary blood flow will be measured in collaboration with Dr Bruce Thompson from the Alfred Respiratory Department. Sodium nitroprusside (SNP) is a known NO donor and will be used as a positive control. Following baseline measurements participants will receive an intravenous (forearm vein) infusion of SNP (titrated from 0.3ug/kg/min to a maximum of 3 ug/kg/min over 30 minutes). Blood pressure will be monitored throughout using an automated sphygmomanometer. Post infusion exhaled NO and pulmonary blood flow will be measured.

Participants will then commence the second phase of the study to determine whether ISMN and PETN increase exhaled NO levels and to determine which drug is more potent in this regard.

Visit 2, 3 & 4: Participants will receive each of the following study medications in a randomised Latin square design:

  • Placebo administered once on the morning of Visit 2, 3 or 4,
  • extended release ISMN mononitrate (120mg ) administered once on the morning of Visit 2, 3 or 4; &
  • pentaerythritol tetranitrate (160mg administered once on the morning of Visit 2, 3 or 4).

There will be a 7-day wash-out period between each treatment/visit. Participants will undergo repeated measures of exhaled NO, pulmonary blood flow and OGTT three hours after each study drug has been administered. Blood will be taken prior to and every hour after the participant has taken each drug for measurement of NO metabolites (e.g. nitrite/nitrate, nitrosothiols, nitrosohemoglobin). Nitrate drugs are occasionally associated with headache and dizziness. Headaches can be treated with paracetamol.

Endpoints at baseline and post treatments will be:

  • Post 75g oral glucose load
  • Exhaled NO levels
  • Pulmonary blood flow

Significance: Once the most effective NO donor has been determined it will be utilized in the chronic nitrate study described in Aim 2.

Aim 2: To determine whether chronic nitrate therapy for 12 weeks improves glucose tolerance and HbA1c in patients with type 2 diabetes.

Twenty male type 2 diabetic subjects aged between 30 and 60 years and meeting the inclusion criteria specified in Aim 1 will be recruited from our clinics and through advertisement. Patients will be randomized to 12 weeks of treatment with both long-acting nitrate therapy (isosorbide mononitrate 60mg daily, Imdur) and placebo (cross-over design). Primary endpoints will be:

  • glycated haemoglobin (HbA1c)
  • whole body glucose uptake at rest (stable glucose tracer methodology, (39-41))
  • whole body glucose uptake after (0-2 hrs) a 75 gm oral glucose load (tracer methodology)
  • skeletal muscle cGMP and GLUT-4 translocation (vastus lateralis muscle biopsy before and after glucose load)
  • skeletal muscle glycogen, lactate, phosphocreatine, creatine and ATP Significance: This study will determine whether chronic nitrate therapy increases GLUT-4 translocation / glucose uptake and has beneficial effects on glycaemic control in patients with type 2 diabetes.

Aim 3:

To determine whether acute infusion of AICAR, an AMP analogue, increases leg glucose uptake at rest in patients with type 2 diabetes.

Twenty healthy males and twenty male type 2 diabetics aged between 30 and 60 years will be recruited from our clinic and through advertisement. The inclusion criteria for the diabetics will be:

  • non-smokers
  • free of overt coronary disease (stress ECG)
  • body mass index < 35 kg.m-2
  • fasting plasma glucose > 7 mmol.L-1 and / or post 75 gm oral glucose load plasma glucose levels of > 11.1 mmol.L-1
  • unmedicated (diet controlled)

The leg blood flow (thermodilution) and glucose uptake (arterial-venous differences) response to a 60 minute intra-femoral infusion of AICAR (1 mg.kg-1.min-1, Clinalfa, Switzerland) using techniques established in our laboratory will be assessed. As a control we will also measure responses to vehicle (saline) infusion prior to commencing the dose response curve (60 min). Plasma free fatty acids, glycerol, triglycerides and lactate will be determined and blood gases will be measured to assess respiratory quotient. Vastus lateralis biopsies will be performed at baseline and after AICAR and the following parameters quantitated:

  • AMPK activity
  • nNOS phosphorylation
  • NOS activity
  • GLUT-4 translocation
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Condition  ICMJE Diabetes Mellitus, Type 2
Intervention  ICMJE Drug: nitroprusside, pentalong, imdur, AICAR, isoptin

Sodium Nitroprusside - one 30 minute intravenous infusion

Pentalong - two tablets orally (total 160mg)

Imdur - two tablets orally (total 120mg)

Study Arms  ICMJE Active Comparator: 1
Intervention: Drug: nitroprusside, pentalong, imdur, AICAR, isoptin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Estimated Enrollment  ICMJE
 (submitted: December 14, 2009)
40
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE April 2009
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

Patients with type 2 diabetes

  • Non-smokers
  • Free of overt coronary disease (stress ECG)
  • Body mass index < 35 kg.m-2
  • Fasting plasma glucose > 7 mmol.L-1 and / or post 75 gm oral glucose load plasma glucose levels of > 11.1 mmol.L-1
  • Unmedicated (diet controlled)

Healthy controls

  • Non-smokers
  • Free of overt coronary disease (ECG)
  • Body mass index < 30 kg.m-2
  • Fasting plasma glucose < 6.1 mmol.L-1
  • Unmedicated
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00168519
Other Study ID Numbers  ICMJE 51/02
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Baker Heart Research Institute
Collaborators  ICMJE
  • National Health and Medical Research Council, Australia
  • Hoffmann-La Roche
  • Diabetes Australia
Investigators  ICMJE
Principal Investigator: Bronwyn A Kingwell, PhD Baker Heart Research Institute
PRS Account Baker Heart Research Institute
Verification Date December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP